Dennis interviews urologist Dr. Michael Curran, founder of Greater Boston Urology, about prostate cancer screening. Curran explains prostate cancer is common and often symptomless, making PSA trends and rectal exams important, and critiques the 2012 USPSTF “D” rating for PSA screening. He outlines higher-risk groups (first-degree family history and African American men) who should start screening at 40, and suggests most men begin around 50, with follow-up intervals based on results. The discussion covers limitations of PSA, biopsy risks, newer tools such as supplemental blood/urine markers, prostate MRI, high-definition ultrasound, and transperineal biopsy, plus treatment options including active surveillance, focal therapies, robotic surgery, and newer radiation approaches. They also discuss no-scalpel vasectomy and safe monitoring for testosterone therapy. Later segments cover competitive eating risks, mixed evidence for creatine in depression, Utah’s AI prescription refills, rectal bleeding as a colorectal cancer red flag, rising alpha-gal syndrome, summer “would you rather,” and Boston sports updates on the Celtics, Red Sox, and Patriots.
04:04 Why Prostate Cancer Matters
07:39 PSA Screening Controversy
14:59 Who Should Screen When
23:04 Modern Biopsy Options
26:52 Treatment Paths Today
29:58 Vasectomy Quick Guide
31:39 Safe Testosterone Therapy
34:48 First PSA Expectations
36:46 Post Interview Wrap
38:03 PSA Screening Debate
39:12 Competitive Eating Risks
41:24 Hot Pepper Pain Tolerance
42:52 Creatine and Depression
47:17 AI Prescription Refills
51:39 Rectal Bleeding Warning
54:33 Tick Bites and Meat Allergy
01:02:26 Summer Would You Rather
01:03:07 Drone Shows vs Fireworks
01:04:01 Firework Mishap Story
01:05:29 Dog Bite or Human
01:06:09 Central AC or Pool
01:08:47 Poison Ivy vs Sunburn
01:10:08 Celtics Jaylen Brown Trade
01:15:40 Red Sox Second Half Outlook
01:19:26 Patriots QB Rankings Talk
01:22:09 Family Anthem News
01:23:28 Wrap Up and Farewell